1. Home
  2. Labeler Index
  3. Waylis Therapeutics Llc
  4. 80725-712
  5. Product Images: Avodart

Product Images Avodart

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Avodart NDC 80725-712 by Waylis Therapeutics Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Dutasteride structural formula - avodart spl image 01

Dutasteride structural formula - avodart spl image 01

Figure 1. AUA-SI Score* Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 02

Figure 1. AUA-SI Score* Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 02

Figure 2. Percent of Subjects Developing Acute Urinary Retention Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 03

Figure 2. Percent of Subjects Developing Acute Urinary Retention Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 03

This text appears to be presenting data related to a clinical trial or study. It includes information about the number of events or outcomes observed in both a placebo group and a group receiving a medication called dutasteride, as well as the number of patients at risk in each group. The numbers seem to be related to a specific time period or duration of treatment, possibly 6 and 12 months. However, without a clearer context or additional information, it is difficult to provide a more specific description.*

Figure 3. Percent of Subjects Having Surgery for Benign Prostatic Hyperplasia Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 04

Figure 3. Percent of Subjects Having Surgery for Benign Prostatic Hyperplasia Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 04

Figure 4. Prostate Volume Percent Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 05

Figure 4. Prostate Volume Percent Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 05

Figure 5. Qmax Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 06

Figure 5. Qmax Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) - avodart spl image 06

Not available.*

Figure 6. - avodart spl image 07

Figure 6. - avodart spl image 07

Figure 7. Q-max Change Ffrom Baseline Over a 24-Month Period (Randomized, Double-Blind, Parallel Group Study [CombAT Study]) - avodart spl image 08

Figure 7. Q-max Change Ffrom Baseline Over a 24-Month Period (Randomized, Double-Blind, Parallel Group Study [CombAT Study]) - avodart spl image 08

Avodart 0.5 mg 90 count label - avodart spl image 09

Avodart 0.5 mg 90 count label - avodart spl image 09

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.